skip to main content
Main Site Navigation
Top of main content
Redefining CancerCare Around You.
Filming this video took place prior to COVID-19 pandemic
WATCH VIDEO
AUDIO DESCRIPTIONS

Research and Clinical Trials

Involved in national research for more than 30 years, Carle Cancer Institute offers its patients access to innovative ways to fight cancer through clinical trials. Clinical trials offer new insight into how to combat a disease like cancer and demonstrate new ways of preventing, treating, or possibly curing cancer.

Carle Cancer Institute provides access to clinical trials for several types of cancer including but not limited to breast, lung, colon, melanoma, prostate, and ovarian cancer. We are also actively involved in national prevention clinical trials per cancer type. In addition, we offer symptom management program to address the quality of life of cancer patients.

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion. --Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die. --The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Infigratinib is an oral medication which selectively binds to fibroblast grown factor receptor (FGFR)-2 and is being developed to treat participants with FGFR-2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral Infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR-2 gene fusions/translocations.

An Open, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an ESR1 mutation.---- The secondary objectives are to evaluate:-- 1.Clinical benefit rate (CBR) and Objective Response Rate (ORR)-- 2.Duration of response-- 3.Time to response-- 4.Overall Survival (OS)-- 5.Pharmacokinetics of lasofoxifene-- 6.Quality of life (QoL)-- 7.Safety of lasofoxifene-- 8.Response to various ESR1 mutation subtypes-- 9.The presence of the following mutations from tumor free DNA will be documented and part of an exploratory analysis:-- a.) erbb2 extracellular domain mutation 5310;-- b.) erbb2 kinase domain mutations V777, L755, and Exon 20 insertion;-- 3.all NF1 mutations that are truncating, frame shifting and nonsense or homozygous deletions; and-- 4.KRAS.

SEE MORE CLINICAL TRIALS

Meet Our Team

With doctors practicing in 80 specialties at locations throughout the region, it’s easy to find the right healthcare team at Carle. Our mission is to serve people through high quality care, medical research and education.

MEET OUR TEAM

Giving

Charitable gifts are used for numerous projects and programs that enhance the healthcare experience for cancer patients and their loved ones. With your support, we’ll continue to work to eliminate cancer through excellence in diagnosis, treatment, research and education. 

DONATE NOW GIVING AT CARLE

Related Events

May 12, 2021
5 p.m.
May 13, 2021
10:30 a.m.

Awards and Accreditations

Recognized among the nation’s top hospitals, Carle provides excellent healthcare while continuously improving to meet the needs of our patients.

  • National Accreditation Program for Breast Cancer
  • Commission on Cancer
  • ACR - Breast Ultrasound Accredited Company
  • QOPI Certified